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Abstract  (224/250 words)
Background: Atopic eczema onset is described primarily in early childhood; 
the frequency and characteristics of adult-onset disease remain 
controversial.
Objective: To determine the proportion of individuals who report atopic 
eczema symptoms between birth and mid adulthood, and to examine 
demographic, immunologic, and genetic factors associated with period of 
symptom onset.
Methods: We conducted a longitudinal study using data from two nationally 
representative community-based birth cohorts from the United Kingdom: the 
British Cohort Studies 1958 and 1970. Individuals were followed from birth 
through age 42-50. The primary outcome was the age period of self-reported
atopic eczema symptom onset based on repeated measures of self-reported 
atopic eczema at each survey wave.
Results: The annual period prevalence of atopic eczema ranged from 5-15%
in two cohorts of over 17,000 participants each followed from birth through 
mid-age. There was no clear trend in prevalence by age, and among adults 
reporting active atopic eczema during a given year, only 38% had symptom 
onset reported in childhood. When compared with individuals whose eczema 
started in childhood, those with adult-onset disease were more likely to be 
women, from Scotland or Northern England, of lower childhood socio-
economic group, smokers in adulthood, and less likely to have a history of 
asthma. In a sub-analysis using data from the 1958 cohort only, genetic 
mutations previously associated with atopic eczema, including filaggrin null 
mutations, and allergen-specific IgE were more common among those with 
childhood-onset disease. 
Conclusion: Rates of self-reported atopic eczema remain high after 
childhood, and adult-onset atopic eczema has different risk factor 
associations than childhood-onset eczema.
Clinical Implication: Adult-onset eczema is common and may be less likely 
to present with other atopic disease.  
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Capsule Summary (29/ 30 words):   In two nationally representative birth 
cohorts followed through mid-life, adult-onset eczema was most common, 
and the strength of association with demographic, immunologic and genetic 
factors differed from childhood-onset disease. 
Key words: atopic eczema, atopic dermatitis, natural history, epidemiology
Abbreviations: 
BCS: British Cohort Study
CI: Confidence interval 
OR: Odds Ratio
UK: United Kingdom
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Introduction
Atopic eczema (also known as atopic dermatitis or just eczema) is the 
leading cause of skin-related disability,(1) but most epidemiological research
has focused only on incidence early in life or patterns of disease in 
childhood.(2) Recent data suggest that atopic eczema is also common 
among adults, but whether these trends are due to increasing persistence of 
disease or new-onset disease later in life is unclear.(3-5) Atopic eczema is 
known to wax and wane over time, yet there are limited longitudinal data on 
patterns of disease activity over the life course. Cross-sectional studies have 
reported proportions of adult-onset atopic eczema ranging from 13-60%.(6-
15) The validity of these estimates have been questioned because of the 
potential for recall bias (adults may not accurately recall whether they had 
eczema as children) or the possibility that disease expression in adulthood is 
due to migration from low to high prevalence climates.(16) In addition, 
studies of dermatology clinic populations suggest that there may be 
important genetic and phenotypic differences in adult-onset disease, but 
these may not be representative of the general population and are 
controversial for the reasons stated above. Data from population-based 
longitudinal birth cohorts are needed to understand the patterns and 
predictors of atopic eczema presentation across the life course.
It is important to understand the epidemiology of adult-onset atopic eczema 
for a number of reasons. First, since most diagnostic criteria specify that 
disease begins early in childhood, patients and providers may feel uncertain 
of the diagnosis in adults with new onset disease. While additional testing is 
often appropriate to rule out differential diagnoses,(17) if many adults don’t 
meet the diagnostic criteria developed for children, they may be subject to 
anxiety about the lack of a clear diagnosis, excessive testing, and limited 
access to new treatment options.(18) Second, if risk factors for adult-onset 
atopic eczema differ, this raises the possibility of a different subtype of 
atopic eczema and could help to elucidate differences in disease 
pathophysiology and drivers of disease activity. Finally, understanding if 
childhood-onset and adult-onset atopic eczema differ is important for refining
preventative and treatment strategies. The latter is particularly timely 
because many new small molecules and biologic agents are currently under 
development and clinical testing for atopic eczema.(18) 
Using two large cohorts followed from birth for 4-5 decades that are 
representative of the general UK population, we sought to determine the 
proportion of individuals who develop symptoms of self-reported atopic 
eczema in childhood and adulthood, and examine factors associated with 
period of onset.
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Methods
We performed a longitudinal cohort study using data from the 1958 and 
1970 British Cohort Studies (BCS 1958 and BCS70), which are ongoing, 
multidisciplinary studies that include 17,196 and 17,415 babies born in Great
Britain during one week in March 1958 and March 1970, respectively.(19, 20)
There have been 8-9 subsequent waves of follow up in each cohort at 
approximately 5-10 year intervals (Figure 1). In the 1958 study, waves at 
ages 33, 46, and 55 did not include data on atopic eczema and thus were not
included in the analysis. Additional information on response patterns in both 
cohorts has been reported elsewhere.(21, 22)
Outcomes
The primary outcome was parental or self-reported period prevalence of 
atopic eczema, based on a standardized question asking about “eczema” 
during or prior to the past year or since the last survey at each wave of 
follow up (Supplemental Table 1). In descriptive analyses, this measure 
coincided well with standardized clinical exams among children in the 1958 
birth cohort,(23, 24) and a similar question has been shown to have high 
sensitivity and specificity for physician-diagnosed atopic eczema in US 
children and adults.(25) We categorized individuals who reported atopic 
eczema into two groups: those whose first report of atopic eczema occurred 
in childhood (positive parental report during or prior to last year at age 5-7 
and/or 10-11), and those with adult-onset atopic eczema (first report of 
atopic eczema at age 23+). For the primary analysis, we did not include 
atopic eczema data from age 16, because it is considered a transitional 
period between pediatric and adult care in the UK, and the 1958 cohort only 
asked about annual period prevalence (rather than period and lifetime 
prevalence at that age). In sensitivity analyses, data from age 16 were 
included. 
Covariates
Additional covariates were chosen based on prior literature showing an 
association with atopic eczema.(23, 26, 27) These included sex, ethnic 
group, history of any breastfeeding, region of residence in childhood, region 
of residence in adulthood (at age 42), childhood smoke exposure (either 
parent reporting current smoking during childhood surveys), smoking in 
adulthood (personal report of current smoking on any of the surveys in 
adulthood), household size (categorized into <=3 persons and 4+ persons), 
in utero smoke exposure (mother reported any smoking during pregnancy), 
birth weight, and the Registrar General’s designation of social class (a 
standard measure based on the father’s highest occupational status reported
on any survey at ages 0-10/11 for childhood, and an individuals’ own 
occupation at ages 23-50 for adulthood). Personal history of asthma or 
allergic rhinitis/hay fever was based on questions repeated at multiple ages 
(Supplemental Table 2). Data on parental history of asthma and hay fever 
was only available in the 1970 cohort, and was based on either parent’s 
report of either condition at age 5. 
Primary analysis 
In both cohorts, we estimated the cumulative lifetime prevalence and the 
age-specific period prevalence. We also calculated the proportion of 
individuals with childhood-onset versus adult-onset disease among those 
who reported active atopic eczema in adulthood. We used multivariable 
logistic regression to test for differences in demographic and risk factors 
between 1) childhood-onset and no atopic eczema, 2) adult-onset and no 
atopic eczema, and 3) childhood-onset versus adult-onset atopic eczema. 
After examining the regression results for consistency in each cohort 
separately, we conducted a meta-analysis of individual participant data, 
assuming fixed effects across studies and accounting for the clustering of 
participants within cohorts.(28) 
Subgroup analysis and biospecimen data
For the subgroup of the 1958 cohort who had biospecimen data available, we
repeated the regressions including variables for the presence of any filaggrin
(FLG) null mutation; and a non-FLG genetic risk score, total IgE, and allergen-
specific IgE modeled as 3-level categorical variables derived as tertiles. 
At the age of 44-45 years, 5,974 individuals in the 1958 cohort were followed
up with a biomedical examination and blood sampling,(29) from which a DNA
collection was established as a nationally representative reference panel. In 
blood samples collected at this adult follow up, the total concentration of 
serum IgE antibodies and the presence of specific IgE to house dust mite, 
mixed grass pollen and cat fur were ascertained by Hytec enzyme 
immunoassay, with a detection threshold of 0.35 kU/L.(30) Four common null
mutations of the FLG gene that have been associated with risk of atopic 
dermatitis in European populations(31, 32) were genotyped directly by LGC 
Genomics using KASPTM genotyping technology. FLG null status was defined 
as the presence of one or more risk variants of rs61816761 (R501X), 
rs150597413 (S3247X), rs558269137 (2282del4) or rs138726443 (R2447X , 
formerly rs386430951). An additional 29 variants outside the FLG region 
were selected for inclusion in a polygenic risk score, based on previously 
published associations with atopic dermatitis (please see supplement for 
additional description of methods and full list of references). A non-FLG 
genetic risk score was generated as the sum of imputed allele dosages for 
the risk-associated variant at each of these SNPs. Additional details are 
provided in the supplemental methods. 
Sensitivity analyses 
For the primary analysis, we did not include atopic eczema data from age 16,
as described above. In a pre-planned sensitivity analysis, we tested the 
impact of this decision on our results by including individuals who reported 
atopic eczema during the past year at age 16 with the childhood onset 
group. We also examined the potential for misclassification bias by 
restricting the sample to those who reported having seen a physician for 
their eczema in the past year, and had no history of self-reported psoriasis or
contact dermatitis.
Missing data
We explored patterns of missing data throughout follow up and found that 
there was both intermittent missing survey data and attrition from the 
cohort. For the primary analysis, we included only individuals with at least 
one survey response in childhood and one survey response in adulthood 
(Figure 1). Additionally, to explore the impact of missing data, we performed 
multiple imputation in each cohort separately with iterative chained 
equations to impute missing exposure, outcome, and covariate data. Thirty 
imputed datasets were generated, and the average results from repeated 
analyses were compared to the complete case analysis. All statistical 
analyses were conducted using Stata, version 14 (StataCorp, Tx). 
Results
At birth, 17,196 individuals were recruited to the 1970 cohort and 17,415 
individuals were recruited into the 1958 cohort. There was intermittent 
missing data and attrition in both cohorts over time; 56-57% of the original 
birth sample responded to the last wave of follow up (Figure 1). Data on 
atopic eczema in both childhood and adulthood were available for 11,886 
members of the 1970 cohort and 13,143 members of the 1958 cohort; 
demographic characteristics and missing covariate data are shown in Table 1
and Supplemental Table 3. 
Consistent with international trends, atopic eczema was more common in the
1970 cohort: the cumulative lifetime prevalence of atopic eczema was 28% 
in the 1970 cohort and 18% in the 1958 cohort. Among those with atopic 
eczema at any time point, 40% and 43% reported disease for the first time in
adulthood in the 1970 and 1958 cohorts, respectively. The period prevalence
of atopic eczema ranged from 7-14% during any given period childhood and 
5-12% during any given period in adulthood (Supplemental Table 1), and 
there was no clear trend across ages in either cohort (Figure 2). Among 
those who reported atopic eczema activity at each survey wave in 
adulthood, the majority (mean 62%) did not have a report of eczema during 
childhood (Figure 3).  
The strength of association from multivariate regression models comparing 
individuals with childhood-onset atopic eczema and adult-onset atopic 
eczema to individuals without atopic eczema differed, as is evidenced by the 
results of the regression model directly comparing those with adult-onset to 
childhood-onset disease (Table 2). We found that individuals with adult-onset
atopic eczema were more likely to be women, from Northern geographic 
areas in the UK, from lower social class in childhood, and smoke during 
adulthood; but were less likely to have a history of asthma (Table 2). 
In a sub-group analysis using data from 3,365 individuals in the 1958 cohort 
who were part of the biomedical follow up at age 44-45 and had atopic 
eczema, genetic, IgE, and covariate data available, we examined rates of 
known risk alleles for AD and both total IgE and allergen-specific IgE.  We 
found that 21% of those with childhood-onset disease, 13% with adult-onset 
disease, and 10% of those without any history of atopic eczema had at least 
one FLG null mutation (Table 1). Both childhood-onset and adult-onset atopic
eczema were associated with FLG null mutations, but the association was 
stronger for childhood-onset than adult-onset in multivariable analyses (OR 
2.73, 95%CI 2.06-3.63, and OR 1.49, 95%CI 1.01-2.19, respectively; Table 3).
A high non-FLG genetic risk score predicted childhood-onset atopic eczema, 
but there was little evidence for an association between the non-FLG genetic 
risk score and adult-onset disease (OR 1.81 95% CI 1.37-2.40, and OR 1.18, 
95%CI 0.85-1.64, respectively; Table 3). Similarly, a high allergen-specific IgE
predicted childhood-onset atopic eczema, but there was little evidence for an
association between the allergen-specific IgE and adult-onset disease (OR 
1.90, 95%CI 1.32-2.74, and 0.86, 0.54-1.36, respectively; Table 3).
Analyses after multiple imputation to address missing data showed similar 
results (Supplemental Table 4). In a sensitivity analysis using data from age 
16, we found that an additional 260 individuals would be classified as having 
childhood-onset disease in the 1970 cohort and an additional 193 children in 
the 1958 cohort. The overall proportion with childhood-onset disease 
remained near 60% in both cohorts, and the results of the regression 
analyses did not change (Supplemental Table 5). Finally, when we excluded 
patients who had a history of contact dermatitis or psoriasis, or did not 
report seeing a physician in the past year for their atopic eczema 
(Supplemental Table 6), we again found similar results (Supplemental Table 
7). 
Discussion
Using two large population-based cohorts followed from birth into midlife, we
found the period prevalence of self-reported atopic eczema was 5-14%. One 
of the defining characteristics of childhood atopic eczema is early age at 
onset; however, the majority of those reporting symptoms in adulthood did 
not have disease onset in childhood. When comparing those with childhood-
onset and adult-onset atopic eczema, we found differences in demographic 
characteristics, atopic comorbidities, IgE profile in adulthood, and genetic 
risk factors. Our findings help to address the gap in knowledge about the 
epidemiology of adult atopic eczema, and suggest that there may be 
different subtypes of adult disease that warrant additional characterization. 
 
Strengths and limitations
Our study is unique in that there is prospective follow up of individuals 
residing in the UK from birth through mid-age. The data come from two large
community-based cohorts broadly representative of the UK general 
population. Consistent with previous reports and international trends,(33-35) 
we found that the overall prevalence of atopic eczema increased between 
1958 and 1970; but there did not appear to be a difference in trends across 
calendar year (Supplemental Figure 1). Two population-based mail surveys in
the US and Italy also found high rates of adult-onset disease (54% and 60% 
of the population respectively,(7, 36)), but have been questioned because of 
the possibility for poor recall of childhood disease or migration to new 
climates.(16) These biases are unlikely to affect our estimates since 
individuals in our cohorts were born in the UK and followed with repeated 
assessments from birth through mid-life. We likely found a lower proportion 
of individuals with early-onset disease because our data included a longer 
duration of prospective follow-up than prior studies.(37) For example, an 
older study using data available through age 23 from the 1958 BCS 
concluded that of the 870 cases by the age of 16 years, 66% had age of 
onset by the age of 7 years.(38) By comparison, using the same initial data, 
now with extended follow-up through age 50, we found only 41% had onset 
of symptoms by age 7. Longitudinal studies of asthma have similarly found 
higher rates of late-onset and recurrent disease with longer periods of follow 
up.(39, 40) 
A limitation of our study is that our outcome of atopic eczema was based on 
parental- or self-report and it is likely that some patients were misclassified. 
Misclassification could include other forms of eczema, including stasis 
dermatitis and irritant contact dermatitis in adults. Nearly all of the 
population-based epidemiologic literature on atopic eczema has relied on 
self-reported assessment of disease, and prior studies have shown that self-
report performs reasonably well: in a multi-center US study with physician 
diagnosis as the gold standard, the positive predictive value of self-report 
was 0.87, 95% CI 0.78-0.96 in children and 0.76, 95% CI: 0.64-0.85 in adults.
(25) Of note, it performed better for children than adults, and the study was 
conducted with dermatology clinic patients where the prevalecne of atopic 
eczema was higher than the general population, meaning the estimates 
could be slightly inflated.  Additional analyses to examine the potential for 
misclassification including restricting our sample to those who reported 
having seen a physician for their atopic eczema and never reported contact 
dermatitis and psoriasis were similar to the primary regression results 
(Supplemental Table 7). While these results do not rule out the potential for 
misclassification bias, they suggest that the magnitude of bias is likely to be 
small. Furthermore, as described in more detail below, our findings on 
filaggrin mutations, IgE, and demographic factors are similar to smaller 
studies of clinical populations with physician-diagnosed atopic eczema. (15, 
16, 41, 42)
An additional limitation of our study is that surveys were fielded at multi-year
intervals and we cannot rule out the possibility that atopic eczema may be 
underreported. For example, some parents may not recall a history of early 
or mild atopic eczema when asked at age 5-7 of their child’s life; however, 
the recall is likely to be superior to surveys of adults asked about their own 
early childhood disease decades later.(43) Similarly, many of the adult 
surveys only asked about atopic eczema during the past year (as shown in 
supplemental table 1), and our results may underestimate adult-onset atopic
eczema.  Detailed phenotypic assessments of participants to detect atopic 
eczema at frequent intervals would be desirable, but they are impractical in 
large population-based cohorts followed for over 40 years.
Finally, as with any long-term study, the data are limited by attrition over 
time. Prior research has shown that in the 1970 cohort, there is a weak 
predictive effect of sex and socioeconomic status on response: men from 
lower social backgrounds with less educated parents are less likely to 
respond, which has previously been described in detail.(44) Because the 
cohort was not explicitly designed to study atopic disease, it is unlikely that 
attrition was differential by atopic eczema status. Nonetheless, to address 
missing data issues, we performed multiple imputation and found results 
that were consistent with the complete-case analysis. 
Implications for research and clinical practice 
Our results highlight the need for additional research to better characterize 
adult eczema and understand whether the pathophysiology differs by age of 
onset. Atopic eczema is known to have a multifactorial etiology, and we 
found genetic, immunologic, demographic, and risk factor differences 
between childhood onset and adult onset disease. Only a few other smaller 
studies have explicitly addressed age-associated differences in atopic 
eczema, and their findings are largely consistent with our results. Studies 
from dermatology clinic populations in Germany and the US also found that 
those with self-reported adult-onset disease were more likely to be 
female(42) and less likely to have a personal or family history of atopic 
disease(41, 42) elevated IgE levels;(41, 45) or filaggrin mutations,(46, 47) 
but did not find differences by smoking or socioeconomic status.(42) In 
contrast, a small case-control study from Taiwan found both current and ever
smoking were strong independent risk factors for adult-onset disease,(48) 
and a recent meta-analysis found high rates of smoking in adults with AD 
overall, but did not differentiate by age of onset.(49) 
Atopic eczema is considered to be a clinical diagnosis, and the most widely 
used diagnostic criteria (the Hanifin and Rajka criteria, the UK Working Party 
criteria refinement of the Hanifin and Rajka criteria, and the American 
Academy of Dermatology criteria) all include early age at onset and history 
of atopy.(50) Clinicians evaluating adults with a potential diagnosis of atopic 
eczema should recognize that the majority of patients may not have 
symptom onset in childhood. Moreover, while individuals with adult-onset 
disease have a higher probability of having a history of other atopic disease 
than individuals without atopic eczema, asthma is only present in about 1/3 
and allergic rhinitis in about ½ of atopic eczema patients (Table 1). 
Diagnostic criteria were developed based on expert opinion among 
dermatologists whose clinical experience may not reflect the distribution of 
disease in the general population, and none have been validated in a 
population-based study of adults.(51) Our data highlight the need to better 
understand what is adult “atopic” eczema and to refine diagnostic criteria for
use in the general adult population. In the meantime, clinical trials of adult 
“atopic” eczema should describe the method by which physicians made the 
diagnosis (if any) and whether validated diagnostic criteria were used that 
would permit exploration or study heterogeneity and subgroup analyses in 
future meta-analyses.”
Terminology 
We choose to use the term atopic eczema based on a call for consistency in 
the literature.(52) There are regional variations in terminology; in the UK, the
term ‘eczema’ is considered more precise than ‘dermatitis’; while in the US, 
the term ‘atopic dermatitis’ is usually preferred.(52) In either case, use of the
term ‘atopic’ has been debated because, even among children, not all 
disease is associated with elevated IgE levels or comorbid atopic conditions 
including asthma or rhinitis. Indeed, previous research has suggested that 
the majority of what is called atopic eczema is not atopic at a population-
level.(53) Our findings that adult-onset disease was associated with lower 
rates of IgE and asthma further call into question the use of the term ‘atopic’
in adult disease; nonetheless, we have continued to use this terminology for 
consistency and clarity. Future studies may uncover subtypes of adult-onset 
disease that require new terminology. 
Conclusion
We found that self-reported adult-onset atopic eczema is common among 
two community-based British cohorts. Differences in genetic, demographic, 
and immunologic profiles between childhood-onset and adult-onset disease 
suggest there may be different subtypes of atopic eczema and emphasize 
the need for better characterization of adult-onset disease and validation of 
diagnostic tools in this population. These data are particularly timely 
because dozens of new treatments are under development and clinical 
testing for AD,(18) and trial populations selected on the basis of early onset 
disease are unlikely to be representative of the general population of adults. 
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